Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
An image from this article is featured on the cover of this edition of Blood Advances, a semimonthly medical journal published by the American Society of Hematology. The cover figure of&
Read morePenn's Gene Therapy Startup Raises Another $50 Million
Funding for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions.
Read moreNational Blood Foundation Early-Career Grant for Dr. Vijay Bhoj
Award for research in the fields of transfusion medicine and cellular therapies.
Read moreStem Cell Lab Part of New Treatment for Lung Complications
Nationwide trial using adult stem cells to battle Acute Respiratory Distress Syndrome.
Read moreFDA Approves CAR-T Immunotherapy for 2nd Indication
Approval for a personalized cellular therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
Read moreFDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read more
